title: Probing inhibitors binding to human urokinase crystals by Raman microscopy: implications for compound screening.
abstract: Inhibition of urokinase activity represents a promising target for antimetastatic therapy for several types of tumor. The present study sets out to investigate the potential of Raman spectroscopy for defining the molecular details of inhibitor binding to this enzyme, with emphasis on single crystal studies. It is demonstrated that high quality Raman spectra from a series of five inhibitors bound individually to the active site of human urokinase can be obtained in situ from urokinase single crystals in hanging drops by using a Raman microscope. After recording the spectrum of the free crystal, a solution of inhibitor containing an amidine functional group on a naphthalene ring was added, and the spectrum of the crystal-inhibitor complex was obtained. The resulting difference Raman spectrum contained only vibrational modes due to bound inhibitor, originating from the protonated group, i.e., the amidinium moiety, as well as naphthalene ring modes and features from other functionalities that made up each inhibitor. The identification of the amidinium modes was placed on a quantitative basis by experimental and theoretical work on naphthamidine compounds. For the protonated group, -C-(NH2)(2)(+), the symmetric stretch occurs near 1520 cm(-1), and a less intense antisymmetric mode appears in the Raman spectra near 1680 cm(-1). The presence of vibrational modes near 1520 cm(-1) in each of the Raman difference spectra of the five complexes examined unambiguously identifies the protonated form of the amidinium group in the active site. Several advantages were found for single crystal experiments over solution studies of inhibitor-enzyme complexes, and these are discussed. The use of single crystals permits competitive binding experiments that cannot be undertaken in solution in any kind of homogeneous assay format. The Raman difference spectrum for a single crystal that had been exposed to equimolar amounts of all five inhibitors in the hanging drop showed only the Raman signature of the compound with the lowest K(i). These findings suggest that the Raman approach may offer a route in the screening of compounds in drug design applications as well as an adjunct to crystallographic analysis.
authors.affiliation: Department of Biochemistry, School of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106-4935, USA.
authors.forename: J
authors.initials: J
authors.lastname: Dong
authors.forename: K
authors.initials: K
authors.lastname: Swift
authors.forename: E
authors.initials: E
authors.lastname: Matayoshi
authors.forename: V L
authors.initials: VL
authors.lastname: Nienaber
authors.forename: M
authors.initials: M
authors.lastname: Weitzberg
authors.forename: T
authors.initials: T
authors.lastname: Rockway
authors.forename: P R
authors.initials: PR
authors.lastname: Carey
mesh_terms: D001665:Binding Sites; D018360:Crystallography, X-Ray / Q000379:methods*; D006801:Humans; D007700:Kinetics; D008956:Models, Chemical; D013059:Spectrum Analysis, Raman / Q000379:methods*; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors* / Q000737:chemistry*
chemical_list: D014568:Urokinase-Type Plasminogen Activator